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ABSTRACT
We evaluated the applicability of a Clostridium difficile infection (CDI) risk index developed for
patients at hospital discharge to identify persons at high-risk of CDI in a primary care population.
This retrospective observational study used data from the UK Clinical Practice Research Datalink,
linked with Hospital Episodes Statistics. The risk index was based on the following patient char-
acteristics: age, previous hospitalizations, days in hospital, and prior antibiotics use. Individual risk
scores were calculated by summing points assigned to pre-defined categories for each character-
istic. We assessed the association of risk factors with CDI by multivariate logistic regression. The
estimated CDI incidence rate was 4/10,000 and 2/10,000 person-years in 2008 and 2012, respec-
tively. On an index with a maximal risk of 19, a cut-off for high risk of ≥7 had sensitivity, specificity
and positive predictive values of 80%, 87% and 12%, respectively. A high-risk person had a ~ 35%
higher risk of CDI than a low-risk person. Multivariate risk factor analysis indicated a need to
reconsider the relative risk scores. The CDI risk index can be applied to the UK primary care
population and help identify study populations for vaccine development studies. Reassessing the
relative weights assigned to risk factors could improve the index performance in this setting.
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Clostridium difficile is an anaerobic spore forming bacter-
ium, which is commonly found in the environment and
transmitted among humans through the fecal-oral route.1,2
Approximately 3% of healthy adults and up to 66% of infants
have C. difficile in their gut without it causing any harm.
However, it can cause disease when the normal commensal
flora is reduced or absent, for example due to antibiotic
exposure.1 C. difficile cells cause disease by the release of
different toxins which can damage the intestinal mucosa.
Symptoms include diarrhea of varying severity, abdominal
pain, fever, mild to severe and even life-threatening inflam-
mation of the bowel (pseudomembranous colitis).1,3
C. difficile infection has traditionally been considered
as mainly a hospital- or other healthcare facility-acquired
infection, but since the 1990s community-acquired C. difficile
infection reports have increased. In the United States (US),
about 25% of all C. difficile cases in 2011 were reported as
community-acquired.4 A recent review showed that the inci-
dence of community-acquired infection has continued to
increase over the last decade, accounting for up to 41% of
all C. difficile-related cases.5
The US Centers for Disease Control and Prevention (CDC)
has created a risk index to identify hospitalized patients at high
risk of developing C. difficile infection after hospital discharge
based on readily available data.6 One of the aims of generating
this risk index was to identify groups of people at high risk of
infections with C. difficile for recruitment to clinical trials for the
development of vaccines.6 Currently there is no vaccine available
against C. difficile. Identifying a target population for future clin-
ical trials in support of vaccine development is essential.
In the present study, we examined the feasibility of apply-
ing the CDC risk index to data originating in primary care
settings across the United Kingdom (UK) and its ability to
identify groups at high risk of C. difficile infection in
a general, unselected population of adults aged ≥18 years
old. We also assessed the predictive value of potential risk
factors for C. difficile infection and their relative importance
when adjusting for the impact of other potential risk factors.
Widely recognized risk factors are hospitalization, advanced
age and prior antibiotics use.7 However, the causes of the changing
epidemiology and the impact of possible new risk factors are yet to
be elucidated.2 Several studies have been published identifying risk
factors for C. difficile infection and developing prediction rules
with the aim to improvemanagement of individuals deemed to be
at the highest risk.6,8–25 Most of these studies target patients
admitted to hospitals or living in long-term healthcare
facilities.9–11,17–19,22–24,26–28 or C. difficile infection cases risking
recurrence.13,19,21,25
The present study adopts a novel approach by targeting
a general, unselected population of adults in the primary care
setting coupled with secondary care data for the same population
to aim for a comprehensive detection of cases of C. difficile
infection.
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Results
Overall incidence of C. difficile infection
Data were extracted from the Clinical Practice Research Datalink
(CPRD) GOLD database, which is linked to secondary care data-
sets, including the Hospital Episodes Statistics (HES), and con-
tains details of all hospital admissions (admitted patient care
[APC]), outpatient visits, and emergency unit attendances at
National Health Service (NHS) hospitals in the UK. Between
January 2008 and March 2012, 3,576 C. difficile infection cases
were identified in the CPRD/HES population subjects, including
all those aged 2 years of age or older and 114,395 C. difficile
infection cases recorded by the PHE surveillance system in
the entire English population. The annual incidence rate in the
CPRD/HES dataset was 4/10,000 person years (PY) in 2008 and
decreased from year to year to 2/10,000 PY in 2012 (Figure 1A).
Public Health England (PHE, formerly the Health Protection
Agency) data also showed a declining trend from 8/10,000 PY in
2008 to 3/10,000 PY in 2012 (Figure 1B).
Demographics and risk factor characteristics
Table 1 compares the CPRD/HES study population with the US
population for which the C. difficile infection risk index was
developed, in terms of the co-variates (and categories) on which
the CDC risk index is based. The CPRD/HES adult study popula-
tion included 2,492,493 individuals aged ≥18 years. The age and
sex distribution were similar in the 2 populations. Prior to the
inpatient hospital stay, at the end of which the US study popula-
tion was recruited at discharge, the vast majority had not been
hospitalized; almost all the individuals in the CPRD/HES study
population had no inpatient hospital stay during the risk assess-
ment period.With regards to antibiotic use, 7% of the CPRD/HES
study population had used antibiotics in the 90 days before the
index date, whereas 45% of the CDC patients had used antibiotics
during the corresponding time period.
Risk classification of the study population
The receiver operating characteristics (ROC) curve presented
in Figure 2 shows the sensitivity and 1-specificity of the risk
index for C. difficile infection within 90 days of the index date
for varying cut-off values. An analysis by risk score cut-off
value was attempted informally to optimize the selection of
the cut-off risk score by assessing the trade-off between sen-
sitivity and specificity. The highest of the calculated risk
scores was 19. Details of the specificity, sensitivity, positive
likelihood ratio (LR+) and the percentage of subjects correctly
classified for varying cut-off values of the risk score are given
in Supplementary Material, Table SM1.
Applying the CDC risk score cut-off value of 4 used by
Baggs et al.,6 the odds ratio (OR) of developing C. difficile
infection within 90 days of the index date was 26 times higher
in high-risk than in low-risk individuals (OR = 25.79, 95%
confidence interval [CI]: 13.79–48.24). With the cut-off value
Figure 1. All C. difficile infection cases and the crude annual incidence rates per 10,000 person-years for CPRD/HES (A) and PHE (B) n: number of cases,
CPRD: Clinical Practice Research Datalink database, HES: Hospital Episode Statistics database, PHE: Public Health England database * 2012 contains data from 1st
January – 31st of March only. The crude rate is based on estimated full year data (2012 figures were multiplied by 4 to make full year estimates).
Table 1. Demographics for the CPRD/HES and CDC study populations.
Characteristic CPRD/HES population N (%) CDC population* N (%)
Study population size 2,492,493 (100) 35,186 (100)
Sex
Men 1,200,764 (48.18) 13,917 (39.55)
Women 1,291,729 (51.82) 21,269 (60.45)
Age (years)
18–39 876,217 (35.15) 11,715 (33.29)
40–49 477,103 (19.14) 4,941 (14.04)
50–64 597,993 (23.99) 8,260 (23.48)
65–74 275,752 (11.06) 4,253 (12.09)
75+ 265,428 (10.65) 6,017 (17.10)
Number of hospitalizations in previous 90 days
0 2,465,563 (98.92) 31,267 (88.86)
1 23,324 (0.94) 3,020 (8.58)
2+ 3,606 (0.14) 899 (2.55)
Length of stay (days)
0 2,465,578 (98.92) N/A
1–3 15,888 (0.64) 21,381(60.77)
4–9 5,422 (0.22) 10,394 (29.54)
10+ 5,605 (0.22) 3,411 (9.69)
Number of antibiotic classes used in previous 90 days
0 2,328,598 (93.42) 19,208 (54.59)
1 150,351 (6.03) 9,102 (25.87)
2 12,580 (0.50) 4,116 (11.70)
3 910 (0.04) 1,782 (5.06)
4 51 (0.00) 676 (1.92)
5+ 3 (0.00) 302 (0.86)
*Data from Baggs et al.6
N: number of persons, %: percentage of persons in this category out of the total
study population, CPRD: Clinical Practice Research Datalink database, HES:
Hospital Episode Statistics database, CDC: US Centers for Disease Control and
Prevention.
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of 4, the sensitivity of the risk index was 98% and the speci-
ficity was 35%. Thirty-five percent of cases were correctly
classified and the LR+ was 1.51. Table SM1 presents the
sensitivity, specificity, proportion of correctly classified and
LR+ for all possible values of the cut-off.
Informal, visual inspection of the ROC curve in Figure 2
suggests that a cut-off value of 7 could result in optimization
of the trade-off between sensitivity and specificity. Thus,
defining high risk as a score ≥7, the sensitivity was 80% and
specificity 87%; the positive predictive value (PPV) was 0.12%,
the LR+ increased to 5.98 and 87% of C. difficile infection
cases were being correctly classified. The summary statistics
indicating the discriminatory capacity of the risk index at cut-
off values of 4 and 7, respectively, are summarized in Table 2,
which includes the summary statistics for C. difficile infection
cases with onset within 365 days of the index date in addition
to those with onset within 90 days.
The cut-off risk score of 7 categorized 2,157,076 (86.5%) indi-
viduals as low-risk and 335,417 (13.5%) as high-risk (Table 3).
Altogether, 490 cases of C. difficile infection occurred within
90 days of the index date, 96 (19.6%) in individuals classified as
low-risk and 394 (80.4%) in those identified as high-risk.
In the low-risk group, the overall proportion with C. difficile
infection was 0.0045% and the proportion was similar in men
and women. The proportion with C. difficile infection increased
10-fold with age, from 0.0014% in the 18–39-year-old group to
0.015% in those aged 65–74 years. There were no individuals
aged ≥75 years with C. difficile infection.
In the high-risk group, the overall proportion with
C. difficile infection was 0.12%, similar for men and
women. The proportion was between 8 and 10 times higher
in the age group 18–39 years than in the older age groups.
For individuals with previous hospitalization, the overall
proportion with C. difficile infection was 0.68%; those with
2 or more hospital stays were infected more than twice as
often as those with 1 hospital stay, 1.37% versus 0.56%. The
proportion of infected individuals also increased with the
length of hospital stays to 1.98% for those with stays of
≥10 days, which is 10-fold higher than for those with stays
of 1–3 days. Among individuals having used antibiotics prior
to the index date, the proportion with C. difficile infection
increased from 0.12% among those having used 1 class to
0.38% among those having used 3 classes.
Figure 2. Receiver operating characteristic curve for varying risk scores for
C. difficile infection within 90 days.
Note: Area under the receiver operating characteristic curve = 0.8926.
Table 2. Risk classification and C. difficile infection within 90 days or 365 days of index date with cut–off risk scores set to either 4 or 7 (sensitivity analysis).
Cut–off value = 4 Cut–off value = 7
90 days 365 days 90 days 365 days
Case Non–case Case Non–case Case Non–case Case Non–case
High–risk 480 1,621,077 1,290 1,620,267 394 335,023 983 334,434
Low–risk 10 870,926 42 870,894 96 2,156,980 349 2,156,727











PPV 0.03 0.08 0.12 0.29
NPV 99.99 99.99 100 99.98
LR+ 1.51 1.49 5.98 5.50
High–risk: persons with a risk score ≥ 4 (cut–off value = 4) or ≥ 7 (cut–off value = 7); Low–risk: persons with a risk score < 4 (cut–off value = 4) or < 7 (cut–off
value = 7); OR: odds ratio; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio.
Table 3. The study population by risk status and C. difficile infection status
within 90 days of the index date.
C. difficile infection (90 days)















Men 46 (47.92) 1,065,758 (49.41) 166 (42.13) 134,794 (40.23)
Women 50 (52.08) 1,091,222 (50.59) 228 (57.87) 200,229 (59,77)
Age (years)
18–39 12 (12.50) 875,769 (40.60) 5 (1.27) 431 (0.13)
40–49 13 (13.54) 472,429 (21.90) 5 (1.27) 4,656 (1.39)
50–64 33 (34.38) 557,364 (25.84) 22 (5.58) 40,574 (12.11)
65–74 38 (39.58) 251,418 (11.66) 36 (9.14) 24,260 (7.24)
75+ 0 (0.00) 0 (0.00) 326 (82.74) 265,102 (79.13)
Previous hospitalization
0 94 (97.92) 2,152,144 (99.78) 244 (61.93) 313,081 (93.45)
1 1 (1.04) 4,435 (0.21) 106 (26.90) 18,782 (5.61)
2+ 1 (1.04) 401 (0.02) 44 (11.17) 3,160 (0.94)
Length of stay (days)
0 94 (97.92) 2,152,147 (99.78) 244 (61.93) 313,093 (93.45)
1–3 2 (2.08) 4,228 (0.20) 21 (5.33) 11,637 (3.47)
4–9 0 (0.00) 605 (0.03) 20 (5.08) 4,797 (1.43)
10+ 0 (0.00) 0 (0.00) 109 (27.66) 5,496 (1.64)
Previous antibiotics used (number of classes)
0 89 (92.71) 2,080,266 (96.44) 286 (72.59) 247,957 (74.01)
1 6 (6.25) 73,556 (3.41) 88 (22.34) 76,701 (22.89)
2 1 (1.04) 3,031 (0.14) 16 (4.06) 9,532 (2.85)
3 0 (0.00) 120 (0.01) 3 (0.76) 787 (0.23)
4 0 (0.00) 7 (0.01) 1 (0.25) 43 (0.01)
5+ 0 (0.00) 0 (0.00) 0 (0.00) 3 (0.00)
N: total number of cases or non–cases in this risk category; n: number of cases or
non–cases in this category of the variable; %: (n/N) x100.
Antibiotics classes considered for inclusion: Aminoglycosides, 1st to 4th generation
cephalosporins, fluroquinolones, vancomycin IV, betalatamase, penicillins, clinda-
mycin, macorlides, sulfanomides antibiotics, carbapenhems, other antibiotics.
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Logistic regression analysis of risk factors
The 3,526 cases of C. difficile infection in individuals aged
≥18 years were included in univariate and multivariate logistic
regression models to determine the relative weight of the
potential risk factor categories. In the univariate analyses, all
categories of each risk factor were found to be statistically
significant at the p = 0.05 level and were thus retained in the
multivariate analysis. However, there was a high degree of
collinearity between the number of previous hospitalizations
and the total number of days spent in hospital, so the latter
variable was left out of the multivariate analysis.
When controlling for the other risk factors, the strongest
associations with developing C. difficile infection were found
for having been hospitalized twice (OR = 115.36, 95% CI:
104.36–127.51), having been treated with 5 or more classes of
antibiotics (OR = 70.31, 95% CI: 2.55–1934.91) and having been
hospitalized once (OR = 47.76, 95% CI: 43.84–52.03) (Table 4).
Discussion
This study was the first to use the CPRD-linked HES APC
database to estimate the incidence of C. difficile infection in
a primary care setting. Over the 4-year study period, from
January 2008 to March 2012, the incidence of C. difficile
infection was found to fall steadily, with an overall decrease
of the annual incidence rate per 10,000 PY of about 50%.
A similar, although even more pronounced, decrease in the
overall annual incidence rate per 10,000 PY over the same
period was observed in the national surveillance data recorded
by PHE. The validation against the PHE data reinforces the
feasibility of measuring risk factors for C. difficile infection in
the CPRD/HES data. The higher number of C. difficile infec-
tion cases reported in 2008 in the PHE database may be linked
to the epidemic of Toxin B strains of C. difficile infection that
happened at that time in Europe.29
Applying the CDC risk index to the CPRD/HES population to
assess its performance and usefulness in the primary care context
showed that the CDC cut-off value of the risk score of 4 gave
a very low PPV and also a LR+ value close to 1. Selecting 7 as an
alternative cut-off value of the risk score based on visual inspec-
tion of the ROC curve and detailed analyses by risk scores,
resulted in relatively high sensitivity and specificity, correct classi-
fication of 87% rather than 35% of the individuals, and a LR+
value of 5.98. An LR+ value of this order suggests an increased risk
for C. difficile infection of about 35% for the high-risk group
compared to the low-risk group (cf. the examples provided by
McGee in his introduction of the simplified LR+ measure30).
With 4 as the cut-off value for the risk score, 2 thirds of our
study population were in the high-risk group. The cut-off value
of 7 seems to be more appropriate for clinical application in
primary care for a number of reasons. Both the sensitivity and
specificity are higher, meaning that the test is more effective at
distinguishing between individuals at risk and not at risk. It also
means that risk factors beyond age alone are contributing to an
individual’s risk status, whereas the cut-off value of 4 places all
persons aged ≥40 in the high-risk group. The cut-off of 7 also
augmented the PPV to 12% rather than 3%.
Multivariate logistic regression analysis of the risk factors
indicated that the factors with the highest independent associa-
tion with developing C. difficile infection, when controlling for
the other factors, were: having been hospitalized during the
90 days preceding the C. difficile infection episode; having used
4 or more classes of antibiotics over the same period; and being
75 years old or older. The relative scores assigned to the risk
factor categories may in future development of the risk index be
better adapted to a general primary care population by using the
OR estimates derived in the multivariate risk factor analysis.
For comparison with other risk indices for C. difficile infec-
tion used in previous studies, it must first be noted that only few
of these have focused on primary care settings. In a recent study
using a Medicare 5% random sample, representative of the US
Table 4. Logistic regression for assessment of the association of risk factors assessed during the 90 days before C. difficile infection onset.
CDI Univariate analyses Multivariate analysis
Variable Case (N = 3,526) n (%) Non–case (N = 2,488,967) n (%) OR (95% CI) Adjusted OR* (95% CI)
Age (years)
18–39 118 (3.35) 825,446 (33.16) Reference category Reference category
40–49 118 (3.35) 472,152 (18.97) 1.75 (1.35–2.26) 1.67 (1.29–2.16)
50–59 417 (11.83) 600,870 (24.14) 4.85 (3.96–5.96) 3.84 (3.12–4.71)
60–74 614 (17.41) 294,380 (11.83) 14.59 (11.98–17.77) 7.96 (6.53–9.72)
75+ 2,259 (64.07) 296,119 (11.90) 53.37 (44.35–64.22) 15.69 (13.00–18.95)
Hospitalized before
0 878 (24.90) 2,431,332 (97.68) Reference category Reference category
1 1,736 (49.23) 48,703 (1.96) 98.70 (90.96–107.10) 47.76 (43.84–52.03)
2+ 912 (25.87) 8,932 (0.36) 282.74 (257.13–310.91) 115.36 (104.36–127.51)
Length of stay (days)
0 892 (25.30) 2,431,411 (97.69) 0.09 (0.08–0.11)
1–3 125 (3.55) 31,460 (1.26) Reference category Not included in the adjusted model
4–9 313 (8.88) 12,533 (0.50) 6.28 (5.10–7.74)
10+ 2,196 (62.28) 13,563 (0.54) 40.75 (33.99–48.85)
No. of antibiotics classes used
0 2,348 (66.59) 2,278,820 (91.56) Reference category Reference category
1 897 (25.44) 188,347 (7.57) 4.62 (4.28–4.99) 2.07 (1.91–2.25)
2 241 (6.83) 20,203 (0.81) 11.58 (10.13–13.23) 3.34 (2.89–3.85)
3 35 (0.99) 1,508 (0.06) 22.53 (16.07–31.57) 4.94 (3.39–7.20)
4 4 (0.11) 85 (0.00) 45.67 (16.74–124.60) 7.30 (2.31–23.04)
5+ 1 (0.03) 4 (0.00) 242.81 (27.14–2172.16) 70.31 (2.55–1934.91)
CDI: Clostridium difficile infection; OR: odds ratio; CI: confidence interval; N: number of cases or non–cases; n: number of cases (or non–cases) in this category; %: (n/N)x100.
Antibiotics classes considered for inclusion: Aminoglycosides, 1st to 4th generation cephalosporins, fluroquinolones, vancomycin IV, betalatamase, penicillins,
clindamycin, macorlides, sulfanomides antibiotics, carbapenhems, other antibiotics.
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population >65 years of age, high-risk individuals were identified
with the ‘population attributable risk percentage’ (PAR%).12 The
PAR% combines determination of the independent importance
of individual risk factors with an assessment of the prevalence of
each risk factor in the targeted population.12 An exploratory
examination of the applicability of this notion to the results of
our study indicates that the PAR% associated with the risk factor
with the highest OR in themultivariate risk factor analysis would
result in a low PAR%, as only 0.22% of the population had 2 or
more hospitalizations.
Limitations of the study include the fact that the HES APC
data do not record medications used during hospital admis-
sions. Consequently, the use of antibiotics may have been
underestimated for the 1.6% of the population that had been
hospitalized at least once before the risk assessment unless the
use had been recorded in the general practitioner (GP)’s notes
or the GP prescribed continued antibiotics use after discharge
of the patient. The study must also be seen in the light of
general limitations of CPRD data,31 including variations in
data quality due to the data being recorded during routine GP
consultations, rather than for research purposes.
One strength of the study was the large number of indivi-
duals observed, meaning that very precise estimates could be
obtained and that no imputations were made for missing
values. Furthermore, since the risk factors examined are read-
ily available data, no additional data collection was required
for the use of the risk index to identify individuals at elevated
risk for C. difficile infection.
Conclusions
Each of the variables included in the risk score was signifi-
cantly associated with the risk of C. difficile infection (p-value
<0.05). The risk factors identified in this study are well recog-
nized and reported in the literature and our study confirmed
that it is possible to measure them in the CPRD/HES data-
bases, with the proviso that antibiotics use during hospitaliza-
tions may not be captured.
The performance of the CDC score in the primary care
sector using CPRD/HES data was low. Assigning a higher risk
score as cut-off value between low and high risk based on
optimization of the trade-off between sensitivity and specifi-
city improved the performance of the risk index considerably.
However, further refinement beyond adjustment of the cut-off
value is required to increase its usefulness in a primary care
setting. Given the variables now included, a possible improve-
ment would be to adapt the relative weights assigned to the
individual categories of the risk factors. The inclusion of other
readily available variables previously identified as risk factors
for C. difficile infection (such as underlying immunosuppres-
sion, renal insufficiency or history of diabetes, or use of
proton pump inhibitors) could also be considered.
As the overall prevalence ofC. difficile infection is low, the PPV
of any predictive tool remains moderate, meaning that most
individuals classified as high-risk will not developC. difficile infec-
tion. Nevertheless, such tools may be relevant and useful if they
are convenient and inexpensive, especially if they have a negative
predictive value around 100%. The results can optimize the iden-
tification of patients to be targeted for individual C. difficile testing
and epidemiological assessment and potentially, the identification
of antibiotic resistant strains. In addition, they can also be used to
better identify target populations for inclusion in clinical trials for
vaccine development and other preventive interventions against
C. difficile infection.
Methods
This retrospective observational study used data extracted from
the CPRD. The CRPD includes anonymized electronic records
from GPs across the UK. The database contains records including
medical diagnoses, referrals to secondary care, prescriptions, diag-
nostic test results and all other types of care administered as part
of GP routine work. The CPRD GOLD database, linked to the
HES dataset, was used for this study. As of January 2014, the
CPRD contained records of more than 13 million persons of
whom approximately 5.5 million were still active (alive, currently
registered), representing about 8.5% of the UK population during
the study period. The HES data link was available for approxi-
mately 60% of the individuals in the CPRD database.32 CPRD is
broadly representative of the characteristics of patients (in terms
of age, gender and ethnicity) and GP practices in the UK.31,33
The index date for the start of follow up for an individual was
the date of the first record of a C. difficile infection such as his/
her first GP visit or the first prescription during the study period,
to ensure that the individual was active in the cohort. Individuals
with a history of C. difficile infection or exposure to related
treatments (i.e., vancomycin, metronidazole, fidaxomicin) dur-
ing the 90 days prior to the index date were excluded. The risk
assessment was made at the index date for each participant.
To identify C. difficile infection cases, the PHE standard
case definition3 was used. Since 2007, all NHS trusts in
England have been requested to report all cases of C. difficile
infection using this definition in individuals aged 2 years or
older as part of a program of mandatory surveillance of
C. difficile infection initiated in 2004. Based on this definition,
a list of Read codes was established and used for data extrac-
tion from the CPRD/HES dataset.
An analysis of the overall incidence of C. difficile infection
was performed to assess the capture of C. difficile infection
cases in the CPRD/HES dataset compared to that of the
mandatory PHE surveillance.3 For this analysis, individuals
aged 2 years or older were included in the cohort, provided
they met the standard CPRD requirements for acceptability
for research,31 were eligible for the HES link, and had been
included in the database for at least 12 months at the time of
inclusion in the study cohort.
Overall annual incidence rates were calculated for the CPRD/
HES cohort and compared to the incidence rates reported by
PHE as a validation of the CPRD/HES dataset. The incidence
was expressed as the annual incidence rate per 10,000 PY. For
2012, the annual rate was estimated by extrapolation of the
number of cases observed until the end of March.
For the main analysis of the validity of the CDC risk index
and the assessment of the relative importance of the potential
risk factors for C. difficile infection, only individuals aged
18 years or older were included in the study cohort.
The CDC risk index is based on the following co-variates with
respective categories: age (18–39, 40–49, 50–64, 65–74, and 75+),
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previous hospitalizations (0, 1, 2+), length of stay in hospital
(0, 1–3 days, 4–9, 10+), and use of antibiotics (0, 1 class, 2 classes,
3, 4, 5 classes). Previous hospitalizations, length of stay in hospital,
and use of antibiotics classes other than C. difficile-related anti-
biotics were assessed over the 90 days prior to the index date for
the assessment of risk. The reference category for each variable
was given a score of 0 and the number of points assigned to the
other categories is presented in Table SM2.
Further details about the assignment of points to the different
categories may be found in the original paper presenting the
CDC index in a study of adult residents of Emerging Infection
Programs at 2 academic centers; participants were included at
discharge after an inpatient stay in one of the study hospitals,
conditional on having no history of C. difficile infection.6
The primary outcome of the validation analysis was the
risk score of C. difficile infection development ≤90 days or
≤365 days after the risk assessment index date in low-risk and
high-risk individuals, respectively. A ROC curve for the trade-
off between the sensitivity and specificity of the risk index was
generated, and the area under the curve determined.
The performance of the selected index cut-off score in
discriminating between high and low-risk individuals was
summarized in terms of sensitivity, specificity, PPV, negative
predictive value, and its LR+. The latter is a relatively rarely
used measure of diagnosing accuracy and it estimates the
likelihood of a particular finding in a person with the disease
divided by the likelihood of the same finding in a person
without the disease.29
The predictive value of potential risk factors was assessed
by multivariate logistic regression analysis, determining the
OR with corresponding CI for each factor. For the C. difficile
infection cases in these analyses, the presence and ‘grade’ of
the risk factors were assessed for the 90 days prior to the date
of C. difficile infection diagnosis. For cohort participants with-
out C. difficile infection, GP consultations following the index
date were recorded during the study period. The assessment
of risk factors was done for the 90 days period preceding
a randomly chosen consultation from the follow-up period.
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